Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968368 · ClinicalTrials.gov registry record · Phase 3
Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
A Phase 3 study, sponsored by Shield Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 167
- Enrollment target
NCT02968368 is a Phase 3 study that has completed, run by Shield Therapeutics. The registered enrollment target is 167 participants.
The verdict
NCT02968368, a Phase 3 study, has completed, sponsored by Shield Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 167 participants
- Enrollment target
Study Summary
To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
Interventions
- OTHER Placebo
- DRUG Ferric maltol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2018-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02968368
The ClinicalTrials.gov registry entry for NCT02968368 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shield Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02968368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02968368 about?
NCT02968368 is a clinical study titled "Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease". To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
What is the current status of trial NCT02968368?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 167 participants. The study started on 2016-12-01. Estimated completion is 2018-10-10.
What interventions are being tested in trial NCT02968368?
The interventions under investigation include: Placebo (OTHER), Ferric maltol (DRUG).
Who is sponsoring clinical trial NCT02968368?
This trial is sponsored by Shield Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.